Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fallopian Tube Neoplasms”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 829 records · Page 46Linked to original sources
PubMed1976

Primary carcinoma of the Fallopian tube.

A series of 26 unreported cases of primary carcinoma of the Fallopian tube is presented. These cases were collected from seven hospitals in Portland, Oregon, for a period of 10 years, i.e., from 1963 to 1974. No statistical data can be made except to state that seven patients of the 26 are known to be alive and well. Of these seven living patients, two have been followed for over 5 years and five have been followed for over 2 years. All are free of disease at the present time. Three other patients lived over 5 years but finally died of their disease. All of these patients were in the Stage I category except two who were in the Stage II category. This suggests that any breakthrough of the serosa of the Fallopian tube is an ominous sign with poor prognosis. The need for earlier diagnosis and supplementary therapy for Stage II of this disease is discussed.

Aged↗
PubMed1978

Adnexal malignancy detected by cervical cytology.

These case presentations are submitted to focus attention on positive (Class V) cervicovaginal cytologic results compatible with adenocarcinoma in the face of benign endocervical and endometrial tissue and in the absence of clinically detectable adnexal disease. Two patients were found to have primary ovarian malignancy, and one patient had adenocarcinoma of the distal end of the right Fallopian tube. Provided that there is confidence in the cytologic diagnosis and that primary disease has been ruled out elsewhere, the clinician is encouraged to utilize additional diagnostic methods, such as laparoscopic visualization of the pelvis and peritoneal fluid studies, in an attempt to facilitate early diagnosis of nonpalpable adnexal disease.

Adenocarcinoma↗
PubMed1985

A case report of primary adenocarcinoma of the fallopian tube.

The apparently smallest primary adenocarcinoma (2.3 mm in diameter) of the fallopian tube ever described was diagnosed by repeated blind sectioning of the surgical specimen after the preoperative finding of an abnormal cervical Papanicolaou smear and the subsequent finding of abnormal cells in fluid obtained by laparoscopic peritoneal lavage, although a survey of the patient for a primary cancer was negative.

Adenocarcinoma↗
PubMed1986

Primary carcinoma of the fallopian tube.

From 1964 through 1983, 47 patients with a mean age of 63 years underwent primary treatment of fallopian tube carcinoma. Vaginal bleeding, abdominopelvic pain or pressure, and a palpable pelvic mass (or masses) were frequent retrospective clinical associations. Survival analysis demonstrated a rapid initial rate of patient attrition with stabilization after 3 years, resulting in an overall 5-year survival rate of 41%. While independent of age, histologic grade, or original tumor size, patient longevity was significantly decreased (p less than 0.01) by the presence of disease beyond the pelvis, neoplastic cells in the peritoneal washings, and size of residual disease. Therapy consisted of primary surgical resection, usually followed by adjunctive radiotherapy or chemotherapy. Initial sites of relapse were predominantly (88%) within the intraperitoneal cavity. The study supports definitive surgical staging and tumor reduction, as well as more selective adjuvant therapy based on surgical stage and residual tumor size and location.

Adenocarcinoma↗
PubMed1993

Tubal hydatidiform mole.

We report a tubal hydatidiform mole, most likely resulting from dispermic fertilization. Early hatching of the embryo, because of a defective zona pellucida, may have favored tubal implantation.

Adult↗
PubMed1995

Uterine prolapse complicated by endometrial cancer.

OBJECTIVE: An infrequent clinical dilemma arises when a patient with uterine prolapse that is best treated vaginally is discovered to have coexisting endometrial cancer. Often the underlying cancer is only discovered intraoperatively or postoperatively. We have reviewed our experience in this situation in an effort to evaluate efficacy of treatment, strategies to avoid late postoperative discovery of cancer, and general guidelines for optimal treatment. STUDY DESIGN: At the Mayo Clinic from 1950 to 1993, 54 patients with coexisting endometrial carcinoma underwent vaginal hysterectomy with repairs for uterine prolapse. RESULTS: We have retrospectively reviewed these cases for relevant data and survival analysis. Complete follow-up is available for 53 patients, and there were four recurrences. In 19 patients bilateral oophorectomy was not performed for multiple reasons, and one of these patients had a recurrence. Twenty-five percent of all patients had disease confined to the endometrium, and 80% overall had low-grade lesions with superficial or no myometrial invasion. Of the four recurrences, three would have been considered low risk of extrauterine spread, and it is doubtful that an abdominal approach would have yielded additional useful information. No patient required reoperation for recurrent pelvic relaxation. CONCLUSION: We believe that for certain selected patients vaginal surgery for uterine prolapse is adequate treatment in the presence of endometrial cancer. We discuss the selection strategies, exclusion criteria, and general guidelines to optimize care for these challenging patients.

Endometrial Neoplasms↗
PubMed1994

p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6.

Fallopian tube carcinoma is a lethal gynecologic malignancy. Etiologic factors are unknown. No experimental data on molecular alterations exist so far. For an in vitro model, we established the permanent human tubal carcinoma cell line FT-MZ-1. The median doubling time was 14 days with 24.2% in S phase. A point missense mutation of the p53 tumor suppressor gene resulting in the His175 mutant was identified. Aberrant p53 protein accumulated in nucleus and cytoplasm. FT-MZ-1 substantially secreted interleukin 6 (Il-6) coinciding with the inactivation of p53 as a transrepressor on the Il-6 gene promoter.

Base Sequence↗
PubMed1987

Primary carcinoma of the fallopian tube.

The records of 50 patients with primary carcinoma of the fallopian tube referred to postoperative radiotherapy at the Radium Centre of the Finsen Institute, Copenhagen, were reviewed. The most common symptoms were postmenopausal bleeding, vaginal watery discharge and abdominal pain. In 86% of the patients a palpable pelvic tumor was found at preoperative gynecologic examination. Disease was localized to the pelvis (stage I and stage II) in nearly all patients (92%). Ten patients were given radiotherapy as vaginal radium twice combined with deep X-ray to the pelvis, and 38 patients were given radiotherapy as high-voltage irradiation to the pelvis only. The overall survival at 5 years was 50.9%. Still, the role of radiotherapy in the control of this rare disease remains to be established. To obtain a better prognosis for this disease, international cooperative prospective studies are proposed.

Actuarial Analysis↗